Trinity Biotech plc (NASDAQ:TRIB) Sees Large Growth in Short Interest

Trinity Biotech plc (NASDAQ:TRIB) saw a significant growth in short interest in the month of April. As of April 15th, there was short interest totalling 1,900 shares, a growth of 58.3% from the March 31st total of 1,200 shares. Approximately 0.0% of the shares of the company are sold short. Based on an average daily volume of 94,300 shares, the days-to-cover ratio is currently 0.0 days.

Wall Street Analysts Forecast Growth

Separately, StockNews.com assumed coverage on shares of Trinity Biotech in a research report on Wednesday. They set a “buy” rating on the stock.

Trinity Biotech Stock Performance

NASDAQ:TRIB opened at $1.83 on Friday. Trinity Biotech has a 52 week low of $1.79 and a 52 week high of $5.50. The firm has a market cap of $13.95 million, a price-to-earnings ratio of -0.58 and a beta of 1.21. The firm’s 50-day simple moving average is $2.01 and its 200 day simple moving average is $2.24.

Trinity Biotech (NASDAQ:TRIB) last released its quarterly earnings results on Thursday, April 4th. The company reported ($0.68) EPS for the quarter. The company had revenue of $13.43 million for the quarter. Sell-side analysts anticipate that Trinity Biotech will post -1.5 EPS for the current year.

Trinity Biotech Company Profile

Trinity Biotech plc acquires, together with its subsidiaries, develops, manufactures, and markets medical diagnostic products for the clinical laboratory and point-of-care (POC) segments of the diagnostic market in the Americas, Africa, Asia, and Europe. The company offers clinical laboratory products, including diagnostic tests and instrumentation, which detect infectious diseases, such as lyme disease; sexually transmitted diseases consisting syphilis and herpes; SARS-CoV-2; and epstein barr, measles, mumps, toxoplasmosis, cytomegalovirus, rubella, varicella and other viral pathogens, as well as products for the in-vitro diagnostic testing for haemoglobin A1c used in the monitoring and diagnosis of diabetes, and identifying those who are at a risk of developing diabetes.